- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00935545
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
A Phase I Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide ISA-51VG in Pediatric Patients With Recurrent or Refractory Central Nervous System Tumors
This is an open-label, single arm study evaluating a multi-peptide (tumor-associated antigens)/Montanide vaccine in patients < 21 years of age with recurrent or refractory CNS tumors. The study primarily evaluates the safety of this regimen. Secondarily, immunogenicity and anti-tumor effects will be assessed.
The primary aim is to evaluate the safety of subcutaneous injections of tumor associated antigens (TAA) mixed with Montanide ISA-51VG in patients with recurrent or refractory brain tumors.
The secondary aims are to evaluate cellular immune responses induced in patients after subcutaneous injection of TAA mixed with Montanide ISA-51VG and to document tumor response in patients with measurable disease or time to progression in patients without measurable disease following subcutaneous injection of TAA mixed with Montanide ISA-51VG.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Patients with primary central nervous system tumors recurrent or refractory to standard therapy. Patients with recurrent tumors other than refractory anaplastic astrocytoma, glioblastoma multiforme or medulloblastoma must have failed all available second line therapies considered to be standard of care prior to inclusion in this study.
- Patients with tumor histologies which have previously been shown to express at least one of the tumor associated antigens (TRP2, gp100, EphA2 or Her2) are eligible. Patients whose tumors are shown to express at least one of these antigens are also eligible.
- Patients must be HLA A*0201 positive.
- Age < 21 years
- Patients must weigh > 15kg due to the amount of blood required for immune function studies.
- Lansky performance status or Karnofsky performance status > 50. Patients who are unable to walk because of paralysis but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
Adequate organ function:
Hematologic: WBC > 1000/mm3 Absolute lymphocyte count > 500 Hemoglobin > 9 gm/dl (may be transfused to achieve adequate hemoglobin level) Platelet count > 50,000/mm3 INR and PTT < 1.5 x the upper limit of normal
Hepatic: AST/ALT < 2 x the upper limit of institutional normal Total bilirubin < 1.5 x the upper limit of institutional normal
Renal: Serum creatinine < upper limit of normal for the patient's age
- Life expectancy > 3 months
- Patients must have fully recovered from previous surgery, chemotherapy, radiotherapy and biologic therapy. No chemotherapy, radiation therapy or immunotherapy within 4 weeks prior to the first dose of study agent (6 weeks for nitrosureas)
- Measurable disease is not required.
- Informed consent must be signed by the patient or legal representative.
Exclusion Criteria
- Serious illness, eg, uncontrolled infections requiring antibiotics.
- History of immunodeficiency disease (such as HIV) or autoimmune disease except vitiligo.
- Concomitant treatment with systemic corticosteroids greater than physiologic doses. Topical (but not at the proposed vaccination site) or inhalational steroids are permitted.
- Participation in any other clinical trial involving another investigational agent within 4 weeks prior the first dose of study agent.
- Pregnant or lactating women are not permitted.
- Women of child-bearing potential not using medically acceptable means of contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open Label
|
Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines.
Although its precise mode of action is not known, it acts to enhance the immune response to vaccination.
It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary aim is to evaluate the safety of subcutaneous injections of tumor associated antigens (TAA) mixed with Montanide ISA-51VG in patients with recurrent or refractory brain tumors.
Time Frame: 2-4 weeks
|
2-4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate cellular immune responses induced in pts after injection of TAA mixed with Montanide and document tumor response in pts w/ measurable disease or time to progression in pts without measurable disease following injection of TAA mixed w/ Montanide.
Time Frame: 2-4 weeks
|
2-4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sharon Gardner, MD, NYU Langone Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08-1017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumors, Central Nervous System
-
Abramson Cancer Center of the University of PennsylvaniaCompletedSuspected Central Nervous System TumorsUnited States
-
Brian LallyCompletedBrain and Central Nervous System TumorsUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Rabin Medical CenterUnknownCentral Nervous System Tumors | TumorsIsrael
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnBrain and Central Nervous System Tumors
-
European Organisation for Research and Treatment...CompletedBrain and Central Nervous System TumorsSwitzerland, United Kingdom, Belgium, Netherlands, Portugal, Austria, Germany, Italy
Clinical Trials on Montanide
-
Centre Hospitalier Universitaire VaudoisLudwig Institute for Cancer ResearchCompleted
-
Centre Hospitalier Universitaire VaudoisImmutep S.A.S.Terminated
-
Sellas Life Sciences GroupUnited States Department of DefenseCompletedMalignant Pleural MesotheliomaUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
University College, LondonAstraZeneca; ShionogiRecruitingBladder CancerUnited Kingdom
-
Nina BhardwajCancer Research Institute, New York CityCompleted
-
Ludwig Institute for Cancer ResearchMemorial Sloan Kettering Cancer CenterCompletedFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CancerUnited States
-
Oryx GmbH & Co. KGCompleted
-
Cytos Biotechnology AGCompletedMalignant MelanomaSwitzerland
-
University of VirginiaCompleted